What Prism TPO does

Prism TPO (legal name: Prism Transparent Purchasing Organization) is a venture-backed Group Purchasing Organization built specifically for independent oncology practices in the United States. Headquartered in Nashville, TN, the company operates a transparent purchasing model that it claims cuts over 80% of traditional drug pricing components (such as retrospective distribution rebates) in favor of upfront, predictable pricing. As of 2024, the Prism network represents over $1.2 billion in annual oncology drug spend across 16 leading independent community oncology practices, and has been recognized by 17 pharmaceutical manufacturers as an official aggregator spanning 36 oncology drug contracts.

The company's core product is the Drug Pricing Transparency Platform, launched in 2025, which integrates live distributor pricing, GPO contract economics, and reimbursement data into a unified view of drug costs. The platform enables practices to assess drug profitability, compare therapeutic alternatives, and make purchasing decisions without relying on siloed spreadsheets. The platform is built on a cloud-native stack using GitHub Codespaces, AWS CDK, and AI-native developer tooling (Cursor IDE). Planned roadmap enhancements include predictive modeling for purchase forecasting and anomaly detection/scenario planning. Prism TPO is a partner of ONCare Alliance, is backed by Obvious Ventures, and is led by Founder & CEO Tesh Khullar alongside a four-person executive team.

The business model is a GPO membership/purchasing fee structure generating recurring revenue through transparent, quote-based pricing with monthly billing. The go-to-market is sales-led, with direct field engagement targeting practice CEOs and Directors of Pharmacy across mid-to-large independent oncology practices. The company emphasizes transparency, alignment with member practices, and direct pharmaceutical manufacturer partnerships as its core value proposition, with reported claims that 95% of switching practices see measurable savings.

Name

Prism TPO

Legal name

Prism Transparent Purchasing Organization

Website

https://prismtpo.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Prism TPO is a transparent Group Purchasing Organization serving independent oncology practices in the U.S., aggregating $1.2B in annual drug spend across 16 practices through a Drug Pricing Transparency Platform and direct pharmaceutical manufacturer partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Nashville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. GPO Membership/Purchasing Fees: Prism TPO operates as a transparent purchasing organization, generating revenue through membership fees and/or transaction-based purchasing fees from independent oncology practices. Practices pay to access the network's collective purchasing power and transparent pricing model.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Prism TPO operates a transparent purchasing organization (GPO) purpose-built for independent oncology practices. Its core offering is the Drug Pricing Transparency Platform, which integrates live distributor pricing, GPO contract economics, and reimbursement data into a unified view, enabling practices to assess drug profitability, compare therapeutic alternatives, and make informed purchasing decisions. The platform is supported by 36 oncology drug contracts across 17 pharmaceutical manufacturers and cuts over 80% of traditional pricing components such as retrospective distribution rebates.

Product overview

Prism TPO operates as the first and only transparent purchasing organization (GPO) built exclusively for independent oncology practices. The core offering is the Drug Pricing Transparency Platform, which integrates live distributor pricing, GPO contract economics, and reimbursement data into a unified dashboard. The platform cuts over 80% of traditional pricing components (such as retrospective distribution rebates), leaving only upfront and predictable pricing. Prism TPO's model is augmented by its network of 18 pharmaceutical partnerships recognized across 36 oncology drug contracts, which provide member practices with clearly defined savings opportunities. The company represents over $1.2 billion in annual oncology drug spend across 16 independent community oncology practices. As a partner of ONCare Alliance, Prism TPO also participates in collaborative industry initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Pricing Transparency Platform A software platform that integrates live distributor pricing, GPO contract economics, and reimbursement data into a unified view of drug costs. It enables independent oncology practices to assess drug profitability, compare therapeutic alternatives, and make informed purchasing decisions without relying on siloed spreadsheets and manual reporting.
• Transparent GPO Membership & Purchasing Network A purchasing organization membership service that gives independent oncology practices access to collective purchasing power, transparent upfront pricing, and direct pharmaceutical manufacturer partnerships across 36 oncology drug contracts. Members pay recurring purchasing and/or membership fees to join the network.

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• ONCare AlliancecoreStrategic or Co-development PartnerPrism TPO is a partner of ONCare Alliance, a network of independent oncology practices. Prism participates in ONCare National Leadership Summit and collaborates on advancing the interests of community oncology providers. Strategic alliance positioning Prism within the independent oncology ecosystem.
• 17 Pharmaceutical ManufacturerscoreStrategic or Co-development PartnerPrism TPO has been recognized by 17 leading pharmaceutical manufacturers as an official aggregator spanning 36 oncology drug contracts. Manufacturers partner with Prism to gain direct pathway to community-based oncology providers through streamlined contracting and rebate management. Enables practices to access competitive, sustainable drug pricing and additional savings opportunities.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Cencora (formerly AmerisourceBergen): Major pharmaceutical distributor with specialty oncology distribution capabilities (including through US Oncology Network). Competes with Prism on the same drug-purchasing economics for community oncology, but with far broader scale and manufacturer relationships.
• Cardinal Health: Top-three U.S. pharmaceutical distributor with specialty drug and oncology distribution capabilities. Comparable to Prism in serving oncology drug purchasing, though as part of a much broader healthcare distribution portfolio rather than a transparent-oncology focus.
• McKesson: Largest U.S. pharmaceutical distributor with extensive specialty/oncology distribution and an embedded oncology GPO (ION Solutions). Overlaps with Prism in oncology drug purchasing and contract aggregation, but operates at vastly greater scale and as part of a diversified portfolio.

Emerging players

• Onco360: A specialty pharmacy focused on oncology and rare-disease therapies that negotiates directly with manufacturers on behalf of patients and providers. Overlaps with Prism in serving oncology drug economics and manufacturer relationships, though delivered through pharmacy fulfillment rather than a GPO model.
• Shields Health Solutions: Specialty pharmacy integrator focused on embedding specialty pharmacy capabilities into health systems and provider practices. Comparable to Prism at the intersection of specialty drug economics and provider enablement, though anchored in health-system partnerships rather than independent practices.
• Asembia: Specialty pharmacy services company that provides contracting, distribution, and patient access services across specialty therapies including oncology. Comparable to Prism in aggregating manufacturer contracts and serving independent specialty providers, but with a broader specialty-pharmacy lens.

Direct peers

• ION Solutions: An oncology-focused GPO and practice services organization (now part of McKesson) that aggregates drug purchasing and provides practice management services for community oncology providers — directly comparable to Prism TPO's target customer, business model, and product category.
• US Oncology Network (McKesson): A network of independent community oncology practices affiliated with McKesson. Directly serves the same customer base as Prism TPO and offers competing practice support, drug-purchasing, and GPO economics to independent community oncologists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prism-tpo

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prism TPO